Recognition of pathogen-associated nucleic acids by endosomal nucleic acid-sensing toll-like receptors

Acta Biochimica et Biophysica Sinica

Volumn 45, Issue 4, 2013, Pages 241-258

  He, Xiaobing ^a   Jia, Huaijie ^a   Jing, Zhizhong ^a   Liu, Dingxiang ^a,b  

^a INSTITUTE OF PLANT PROTECTION   (China)

^b NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

Compartmentalization; Danger signal; Endosomal nucleic acidsensing toll like receptor; Innate immunity; Signaling pathway

Indexed keywords

NUCLEIC ACID; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9;

BACTERIUM; ENDOSOME; GENETICS; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOLOGY; METABOLISM; REVIEW; VIRUS;

BACTERIA; ENDOSOMES; HOST-PATHOGEN INTERACTIONS; HUMANS; NUCLEIC ACIDS; TOLL-LIKE RECEPTOR 3; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8; TOLL-LIKE RECEPTOR 9; VIRUSES;

EID: 84879231418     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gms122     Document Type: Review

References (190)

1. Kawai T and Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011, 34: 637-650.
2. Barbalat R, Ewald SE, Mouchess ML and Barton GM. Nucleic acid recognition by the innate immune system. Ann Rev Immunol 2011, 29: 185-214.
3. Hansena JD, Vojtechb LN and Laingc KJ. Sensing disease and danger: a survey of vertebrate PRRs and their origins. Dev Comp Immunol 2011, 35: 886-897.
4. Kang JY and Lee JO. Structural biology of the toll-like receptor family. Annu Rev Biochem 2011, 80: 917-941.
5. Barton GM and Kagan JC. A cell biological view of Toll-like receptor function: regulation through compartmentalization. Nat Rev Immunol 2009, 9: 535-542.
6. Matsumoto M, Oshiumi H and Seya T. Antiviral responses induced by the TLR3 pathway. Rev Med Virol 2011, 21: 67-77.
7. Yamamoto M and Takeda K. Current views of Toll-like receptor signaling pathways. Gastroent Res Pract 2010, 2010: 240365.
8. Esashi E, Bao M, Wang YH, Cao W and Liu YJ. PACSIN1 regulates the TLR7/9-mediated type I interferon response in plasmacytoid dendritic cells. Eur J Immunol 2012, 42: 573-579.
9. Xia ZP, Sun L, Chen X, Pineda G, Jiang X, Adhikari A and Zeng W, et al. Direct activation of protein kinases by unanchored polyubiquitin chains. Nature 2009, 461: 114-9.
10. Negishi H, Fujita Y, Yanai H, Sakaguchi S, Ouyang X, Shinohara M and Takayanagi H, et al. Evidence for licensing of IFN-gamma-induced IFN regulatory factor 1 transcription factor by MyD88 in Toll-like receptordependent gene induction program. Proc Natl Acad Sci USA 2006, 103: 15136-15141.
11. Chang Foreman HC, Van Scoy S, Cheng TF and Reich NC. Activation of interferon regulatory factor 5 by site specific phosphorylation. PLoS One 2012, 7: e33098.
12. Martinez J, Huang X and Yang Y. Toll-like receptor 8-mediated activation of murine plasmacytoid dendritic cells by vaccinia viral DNA. Proc Natl Acad Sci USA 2010, 107: 6442-6447.
13. Shi Z, Cai Z, Sanchez A, Zhang T, Wen S, Wang J and Yang JH, et al. A novel Toll-like receptor that recognizes vesicular stomatitis virus. J Biol Chem 2011, 286: 4517-4524.
14. Oldenburg M, Krüger A, Ferstl R, Kaufmann A, Nees G, Sigmund A and Bathke B, et al. TLR13 recognizes bacterial 23S rRNA devoid of erythromycin resistance-forming modification. Science 2012, 337: 1111-1115.
15. Shi Z, Cai Z, Wen S, Chen C, Gendron C, Sanchez A and Patterson K, et al. Transcriptional regulation of the novel Toll-like receptor Tlr13. J Biol Chem 2009, 284: 20540-20547.
16. Dieudonné A, Torres D, Blanchard S, Taront S, Jeannin P, Delneste Y and Pichavant M, et al. Scavenger receptors in human airway epithelial cells: Role in response to double-stranded RNA. PLoS One 2012, 7: e41952.
17. Nagyoszi P, Wilhelm I, Farkas AE, Fazakas C, Dung NT, Haskó J and Krizbai IA. Expression and regulation of toll-like receptors in cerebral endothelial cells. Neurochem Int 2010, 57: 556-64.
18. Kaul D, Habbel P, Derkow K, Krüger C, Franzoni E, Wulczyn FG and Bereswill S, et al. Expression of Toll-like receptors in the developing brain. PLoS One 2012, 7: e37767.
19. Alexopoulou L, Desnues B and Demaria O. Toll-like receptor 8: the awkward TLR8. Med Sci (Paris) 2012, 28: 96-102.
20. Vincent IE, Zannetti C, Lucifora J, Norder H, Protzer U, Hainaut P and Zoulim F, et al. Hepatitis B virus impairs TLR9 expression and function in plasmacytoid dendritic cells. PLoS One 2011, 6: e26315.
21. Thompson MR, Kaminski JJ, Kurt-Jones EA and Fitzgerald KA. Pattern recognition receptors and the innate immune response to viral infection. Viruses 2011, 3: 920-940.
22. Edwards AD, Diebold SS, Slack EM, Tomizawa H, Hemmi H, Kaisho T and Akira S, et al. Toll-like receptor expression in murine DC subsets: Lack of TLR7 expression by CD8 alpha- DC correlates with unresponsiveness to imidazoquinolines. Eur J Immunol 2003, 33: 827-833.
23. Poth JM, Coch C, Busch N, Boehm O, Schlee M, Janke M and Zillinger T, et al. Monocyte-mediated inhibition of TLR9-dependent IFN-α induction in plasmacytoid dendritic cells questions bacterial DNA as the active ingredient of bacterial lysates. J Immunol 2010, 185: 7367-7373.
24. Xu LG, Jin L, Zhang BC, Akerlund LJ, Shu HB and Cambier JC. VISA is required for B cell expression of TLR7. J Immunol 2012, 188: 248-258.
25. Chaturvedi A and Pierce SK. How location governs toll-like receptor signaling. Traffic 2009, 10: 621-628.
26. Chockalingam A, Brooks JC, Cameron JL, Blum LK and Leifer CA. TLR9 traffics through the Golgi complex to localize to endolysosomes and respond to CpG DNA. Immunol Cell Biol 2009, 87: 209-217.
27. Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, Knetter CF and Lien E, et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 2004, 5: 190-198.
28. Barton GM, Kagan JC and Medzhitov R. Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nat Immunol 2006, 7: 49-56.
29. Lee CC, Avalos AM and Ploegh HL. Accessory molecules for Toll-like receptors and their function. Nat Rev Immunol 2012, 12: 168-179.
30. Into T, Inomata M, Takayama E and Takigawa T. Autophagy in regulation of Toll-like receptor signaling. Cell Signal 2012, 24: 1150-1162.
31. Saitoh S and Miyake K. Regulatory molecules required for nucleotidesensing toll-like receptors. Immunol Rev 2009, 227: 32-43.
32. Nishiya T, Kajita E, Miwa S and Defranco A. TLR3 and TLR7 are targeted to the same intracellular compartments by distinct regulatory elements. J Biol Chem 2005, 280: 37107-37117.
33. Leifer CA, Brooks JC, Hoelzer K, Lopez J, Kennedy MN, Mazzoni A and Segal DM. Cytoplasmic targeting motifs control localization of tolllike receptor 9. J Biol Chem 2006, 281: 35585-35592.
34. Mouchess ML, Arpaia N, Souza G, Barbalat R, Ewald SE, Lau L and Barton GM. Transmembrane mutations in Toll-like receptor 9 bypass the requirement for ectodomain proteolysis and induce fatal inflammation. Immunity 2011, 35: 721-732.
35. Yang Y, Liu B, Dai J, Srivastava PK, Zammit DJ, Lefrançois L and Li Z, et al. Heat shock protein gp96 is a master chaperones for toll-like receptors and is important in the innate function of macrophages. Immunity 2007a, 26: 215-226.
36. Brooks JC, Sun W, Chiosis G and Leifer CA. Heat shock protein gp96 regulates Toll-like receptor 9 proteolytic processing and conformational stability. Biochem Biophys Res Commun 2012, 421: 780-784.
37. Kiyokawa T, Akashi-Takamura S, Shibata T, Matsumoto F, Nishitani C, Kuroki Y and Seto Y, et al. A single base mutation in the PRAT4A gene reveals differential interaction of PRAT4A with Toll-like receptors. Int Immunol 2008, 20: 1407-1415.
38. Liu B, Yang Y, Qiu ZJ, Staron M, Hong F, Li Y and Wu S, et al. Folding of Toll-like receptors by the HSP90 paralogue gp96 requires a substratespecific cochaperone. Nat Commun 2010, 1: 1-10.
39. Blasius AL, Arnold CN, Georgel P, Rutschmann S, Xia Y, Lin P and Ross C, et al. Slc15a4, AP-3, and Hermansky-Pudlak syndrome proteins are required for Toll-like receptor signaling in plasmacytoid dendritic cells. Proc Natl Acad Sci USA 2010, 107: 19973-19978.
40. Chiang CY, Engel A, Opaluch AM, Ramos I, Maestre AM, Secundino I and De Jesus PD, et al. Cofactors required for TLR7- and TLR9-dependent innate immune responses. Cell Host Microbe 2012, 11: 306-318.
41. Chevrier N, Mertins P, Artyomov MN, Shalek AK, Iannacone M, Ciaccio MF and Gat-Viks I, et al. Systematic discovery of TLR signaling components delineates viral-sensing circuits. Cell 2011, 147: 853-867.
42. Brinkmann MM, Spooner E, Hoebe K, Beutler B, Ploegh HL and Kim YM. The interaction between the ER membrane protein UNC93B and TLR3, 7, and 9 is crucial for TLR signaling. J Cell Biol 2007, 177: 265-275.
43. Kim YM, Brinkmann MM, Paquet ME and Ploegh HL. UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomes. Nature 2008, 452: 234-238.
44. Fukui R, Saitoh S, Matsumoto F, Kozuka-Hata H, Oyama M, Tabeta K and Beutler B, et al. Unc93B1 biases Toll-like receptor responses to nucleic acid in dendritic cells toward DNA-but against RNA-sensing. J Exp Med 2009, 206: 1339-1350.
45. Tabeta K, Hoebe K, Janssen EM, Du X, Georgel P, Crozat K and Mudd S, et al. The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll-like receptors 3, 7 and 9. Nat Immunol 2006, 7: 156-164.
46. Itoh H, Tatematsu M, Watanabe A, Iwano K, Funami K, Seya T and Matsumoto M. UNC93B1 physically associates with human TLR8 and regulates TLR8-mediated signaling. PLoS One 2012, 6: e28500.
47. Fukui R, Saitoh S, Kanno A, Onji M, Shibata T, Ito A and Onji M, et al. Unc93B1 restricts systemic lethal inflammation by orchestrating Toll-like receptor 7 and 9 trafficking. Immunity 2011, 35: 69-81.
48. Crane MJ, Gaddi PJ and Salazar-Mather TP. UNC93B1 mediates innate inflammation and antiviral defense in the liver during acute murine cytomegalovirus infection. PLoS One 2012, 7: e39161.
49. Nickerson KM, Christensen SR, Shupe J, Kashgarian M, Kim D, Elkon K and Shlomchik MJ. TLR9 regulates TLR7- and MyD88-dependent autoantibody production and disease in a murine model of lupus. J Immunol 2010, 184: 1840-1848.
50. Ewald SE, Lee BL, Lau L, Wickliffe KE, Shi GP, Chapman HA and Barton GM. The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. Nature 2008, 456: 658-662.
51. Park B, Brinkmann MM, Spooner E, Lee CC, Kim YM and Ploegh HL. Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9. Nat Immunol 2008, 9: 1407-1414.
52. Sepulveda FE, Maschalidi S, Colisson R, Heslop L, Ghirelli C, Sakka E and Lennon-Duménil AM, et al. Critical role for asparagine endopeptidase in endocytic Toll-like receptor signaling in dendritic cells. Immunity 2009, 31: 737-748.
53. Asagiri M, Hirai T, Kunigami T, Kamano S, Gober HJ, Okamoto K and Nishikawa K, et al. Cathepsin K-dependent toll-like receptor 9 signaling revealed in experimental arthritis. Science 2008, 319: 624-627.
54. Matsumoto F, Saitoh S, Fukui R, Kobayashi T, Tanimura N, Konno K and Kusumoto Y, et al. Cathepsins are required for Toll-like receptor 9 responses. Biochem Biophys Res Commun 2008, 367: 693-699.
55. Ewald SE, Engel A, Lee J, Wang M, Bogyo M and Barton GM. Nucleic acid recognition by Toll-like receptors is coupled to stepwise processing by cathepsins and asparagine endopeptidase. J Exp Med 2011, 208: 643-651.
56. Peter ME, Kubarenko AV, Weber AN and Dalpke AH. Identification of an N-terminal recognition site in TLR9 that contributes to CpG-DNA-mediated receptor activation. J Immunol 2009, 182: 7690-7697.
57. Kasperkovitz PV, Cardenas ML and Vyas JM. TLR9 is actively recruited to Aspergillus fumigatus phagosomes and requires the N-terminal proteolytic cleavage domain for proper intracellular trafficking. J Immunol 2010, 185: 7614-7622.
58. Garcia-Cattaneo A, Gobert FX, Müller M, Toscano F, Flores M, Lescure A and Del Nery E, et al. Cleavage of Toll-like receptor 3 by cathepsins B and H is essential for signaling. Proc Natl Acad Sci USA 2012, 109: 9053-9058.
59. Qi R, Singh D and Kao CC. Proteolytic processing regulates Toll-like receptor 3 stability and endosomal localization. J Biol Chem 2012, 287: 32617-3229.
60. Lee HK, Lund JM, Ramanathan B, Mizushima N and Iwasaki A. Autophagy-dependent viral recognition by plasmacytoid dendritic cells. Science 2007, 315: 1398-1401.
61. Delgado M, Singh S, De Haro S, Master S, Ponpuak M, Dinkins C and Ornatowski W, et al. Autophagy and pattern recognition receptors in innate immunity. Immunol Rev 2009, 227: 189-202.
62. Oh JE and Lee HK. Autophagy in innate recognition of pathogens and adaptive immunity. Yonsei Med J 2012, 53: 241-247.
63. Kuballa P, Nolte WM, Castoreno AB and Xavier RJ. Autophagy and the immune system. Annu Rev Immunol 2012, 30: 611-646.
64. Saitoh T and Akira S. Regulation of innate immune responses by autophagy-related proteins. J Cell Biol 2010, 189: 925-935.
65. Delgado MA, Elmaoued RA, Davis AS, Kyei G and Deretic V. Toll-like receptors control autophagy. EMBO J 2008, 27: 1110-1121.
66. Delgado MA and Deretic V. Toll-like receptors in control of immunological autophagy. Cell Death Differ 2009, 16: 976-983.
67. Zaitseva E, Yang ST, Melikov K, Pourmal S and Chernomordik LV. Dengue virus ensures its fusion in late endosomes using compartmentspecific lipids. PLoS Pathog 2010, 6: e1001131.
68. Taylor MP and Kirkegaard K. Modification of cellular autophagy protein LC3 by poliovirus. J Virol 2007, 81: 12543-12553.
69. Reggiori F, Monastyrska I, Verheije MH, Cali T, Ulasli M, Bianchi S and Bernasconi R, et al. Coronaviruses Hijack the LC3-I-positive edemosomes, ER-derived vesicles exporting short-lived ERAD regulators, for replication. Cell Host Microbe 2010, 7: 500-508.
70. Wong J, Zhang J, Si X, Gao G, Mao I, McManus BM and Luo H. Autophagosome supports coxsackievirus B3 replication in host cells. J Virol 2008, 82: 9143-9153.
71. Taylor MP and Kirkegaard K. Potential subversion of autophagosomal pathway by picornaviruses. Autophagy 2008, 4: 286-289.
72. Ke PY and Chen SS. Activation of the unfolded protein response and autophagy after hepatitis C virus infection suppresses innate antiviral immunity in vitro. J Clin Invest 2011, 121: 37-56.
73. Alexopoulou L, Holt AC, Medzhitov R and Flavell RA. Recognition of double-stranded RNA and activation of NF-kB by Toll-like receptor 3. Nature 2001, 413: 732-738.
74. Audry M, Ciancanelli M, Yang K, Cobat A, Chang HH, Sancho-Shimizu V and Lorenzo L, et al. NEMO is a key component of NF-kB- and IRF-3-dependent TLR3-mediated immunity to herpes simplex virus. J Allergy Clin Immunol 2011, 128: 610-617.
75. Wang T, Town T, Alexopoulou L, Anderson JF, Fikrig E and Flavell RA. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat Med 2004, 10: 1366-1373.
76. Nasirudeen AMA, Wong HH, Thien PL, Xu S, Lam KP and Liu DX. RIG-I, MDA5 and TLR3 synergistically play an important role in restriction of dengue virus infection. PLoS Negl Tropl Dis 2011, 5: e926.
77. Le Goffic R, Balloy V, Lagranderie M, Alexopoulou L, Escriou N, Flavell R and Chignard M, et al. Detrimental contribution of the Toll-like receptor (TLR) 3 to influenza A virus-induced acute pneumonia. PLoS Pathog 2006, 2: e53.
78. Hardarson HS, Baker JS, Yang Z, Purevjav E, Huang CH, Alexopoulou L and Li N, et al. Toll-like receptor 3 is an essential component of the innate stress response in virus-induced cardiac injury. Am J Physiol Heart Circ Physiol 2007, 292: H251-H258.
79. Edelmann KH, Richardson-Burns S, Alexopoulou L, Tyler KL, Flavell RA and Oldstone MB. Does Toll-like receptor 3 play a biological role in virus infections?. Virology 2004, 322: 231-238.
80. Schulz O, Diebold SS, Chen M, Näslund TI, Nolte MA, Alexopoulou L and Azuma YT, et al. Toll-like receptor 3 promotes cross-priming to virus- infected cells. Nature 2005, 433: 887-892.
81. Negishi H, Osawa T, Ogami K, Ouyang X, Sakaguchi S, Koshiba R and Yanai H, et al. A critical link between Toll-like receptor 3 and type II interferon signaling pathways in antiviral innate immunity. Proc Natl Acad Sci USA 2008, 105: 20446-20451.
82. Oshiumi H, Matsumoto M and Seya T. TICAM-1/TRIF, a TLR3 adaptor, is essential for protection against poliovirus infection. Int Immunol 2010, 22: i19.
83. Gowen BB, Hoopes JD, Wong MH, Jung KH, Isakson KC, Alexopoulou L and Flavell RA, et al. TLR3 deletion limits mortality and disease severity due to phlebovirus infection. J Immunol 2006, 177: 6301-6307.
84. Iwakiri D, Zhou L, Samanta M, Matsumoto M, Ebihara T, Seya T and Imai S, et al. Epstein-Barrvirus (EBV)- encoded small RNA is released from EBV-infected cells and activates signaling from Toll-like receptor 3. J Exp Med 2009, 206: 2091-2099.
85. Li K, Li NL, Wei D, Pfeffer SR, Fan M and Pfeffer LM. Activation of chemokine and inflammatory cytokine response in hepatitis C virus-infected hepatocytes depends on Toll-like receptor 3 sensing of hepatitis C virus double-stranded RNA intermediates. Hepatology 2012, 55: 666-675.
86. West J and Damania B. Upregulation of the TLR3 pathway by kaposi's sarcoma-associated herpesvirus during primary infection. J Virol 2008, 82: 5440-5449.
87. Hutchens M, Luker KE, Sottile P, Sonstein J, Lukacs NW, Nún?ez G and Curtis JL, et al. TLR3 increases disease morbidity and mortality from vaccinia infection. J Immunol 2008, 180: 483-491.
88. Zhang SY, Jouanguy E, Ugolini S, Smahi A, Elain G, Romero P and Segal D, et al. TLR3 deficiency in patients with herpes simplex encephalitis. Science 2007, 317: 1522-1527.
89. Tabeta K, Georgel P, Janssen E, Du X, Hoebe K, Crozat K and Mudd S, et al. Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc Natl Acad Sci USA 2004, 101: 3516-3522.
90. Aksoy E, Zouain CS and Vanhoutte F. Double stranded RNAs from the helminth parasite activates TLR3 in dendritic cells. J Biol Chem 2005, 280: 277-283.
91. Carvalho A, De Luca A, Bozza S, Cunha C, D'Angelo C, Moretti S and Perruccio K, et al. TLR3 essentially promotes protective class I-restricted memory CD8-T-cell responses to Aspergillus fumigatus in hematopoietic transplanted patients. Blood 2012, 119: 967-977.
92. Diebold SS, Kaisho T, Hemmi H, Akira S and Reise SC. Innate antiviral responses by means of TLR7- mediated recognition of single-stranded RNA. Science 2004, 303: 1529-1531.
93. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S and Akira S, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004, 303: 1481-1482.
94. Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, Gale NW and Iwasaki A, et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci USA 2004, 101: 5598-5603.
95. Triantafilou K, Orthopoulos G, Vakakis E, Ahmed MA, Golenbock DT, Lepper PM and Triantafilou M. Human cardiac inflammatory responses triggered by Coxsackie B viruses are mainly Toll-like receptor (TLR) 8-dependent. Cell Microbiol 2005, 7: 1117-1126.
96. Triantafilou K, Vakakis E, Orthopoulos G, Ahmed MA, Schumann C, Lepper PM and Triantafilou M. TLR8 and TLR7 are involved in the host's immune response to human parechovirus 1. Eur J Immunol 2005, 35: 2416-2423.
97. Zhang YL, Guo YJ, Sun SH, Su X, Cai K, Wang D and Chen H, et al. Molecular cloning and functional characterization of porcine toll-like receptor 7 involved in recognition of single-stranded RNA virus/ssRNA. Mol Immunol 2008, 45: 1184-1190.
98. Kato H, Sato S, Yoneyama M, Yamamoto M, Uematsu S, Matsui K and Tsujimura T, et al. Cell type specific involvement of RIG-I in antiviral response. Immunity 2005, 23: 19-28.
99. Wang JP, Liu P, Latz E, Golenbock DT, Finberg RW and Libraty DH. Flavivirus activation of plasmacytoid dendritic cells delineates key elements of TLR7 signaling beyond endosomal recognition. J Immunol 2006, 177: 7114-7121.
100. Zhang YL, Guo YJ, Li B and Sun SH. Hepatitis C virus single-stranded RNA induces innate immunity via Toll-like receptor 7. J Hepatol 2009, 51: 29-38.
101. Cervantes-Barragan L, Zust R, Weber F, Spiegel M, Lang KS, Akira S and Thiel V, et al. Control of coronavirus infection through plasmacytoid dendritic-cell-derived type I interferon. Blood 2007, 109: 1131-1137.
102. Kane M, Case LK, Wang C, Yurkovetskiy L, Dikiy S and Golovkina TV. Innate immune sensing of retroviral infection via Toll-like receptor 7 occurs upon viral entry. Immunity 2011, 35: 135-145.
103. Davidson S, Kaiko G, Loh Z, Lalwani A, Zhang V, Spann K and Foo SY, et al. Plasmacytoid dendritic cells promote host defense against acute pneumovirus infection via the TLR7-MyD88-dependent signaling pathway. J Immunol 2011, 186: 5938-5948.
104. Cervantes JL, Weinerman B, Basole C and Salazar JC. TLR8: the forgotten relative revindicated. Cell Mol Immunol 2012, 9: 434-438.
105. Cervantes JL, Dunham-Ems SM, La Vake CJ, Petzke MM, Sahay B, Sellati TJ and Radolf JD, et al. Phagosomal signaling by Borrelia burgdorferi in human monocytes involves Toll-like receptor (TLR) 2 and TLR8 cooperativity and TLR8-mediated induction of IFN-beta. Proc Natl Acad Sci USA 2011, 108: 3683-3688.
106. Mancuso G, Gambuzza M, Midiri A, Biondo C, Papasergi S, Akira S and Teti G, et al. Bacterial recognition by TLR7 in the lysosomes of conventional dendritic cells. Nat Immunol 2009, 10: 587-594.
107. Caetano BC, Carmo BB, Melo MB, Cerny A, dos Santos SL, Bartholomeu DC and Golenbock DT, et al. Requirement of UNC93B1 reveals a critical role for TLR7 in host resistance to primary infection with Trypanosoma cruzi. J Immunol 2011, 187: 1903-1911.
108. Bourgeois C, Majer O, Frohner IE, Lesiak-Markowicz I, Hildering KS, Glaser W and Stockinger S, et al. Conventional dendritic cells mount a type I IFN response against Candida spp. requiring novel phagosomal TLR7-mediated IFN-beta signaling. J Immunol 2011, 186: 3104-3112.
109. Biondo C, Signorino G, Costa A, Midiri A, Gerace E, Galbo R and Bellantoni A, et al. Recognition of yeast nucleic acids triggers a host-protective type I interferon response. Eur J Immunol 2011, 41: 1969-1979.
110. Hochrein H, Schlatter B, O'Keeffe M, Wagner C, Schmitz F, Schiemann M and Bauer S, et al. Herpes simplex virus type-1 induces IFN-αlpha production via Toll-like receptor 9-dependent and-independent pathways. Proc Natl Acad Sci USA 2004, 101: 11416-11421.
111. Lund J, Sato A, Akira S, Medzhitov R and Iwasaki A. Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. J Exp Med 2003, 198: 513-520.
112. Delale T, Paquin A, Asselin-Paturel C, Dalod M, Brizard G, Bates EE and Kastner P, et al. MyD88-dependent and-independent murine cytomegalovirus sensing for IFN-αlpha release and initiation of immune responses in vivo. J Immunol 2005, 175: 672367-32.
113. Zhu J, Huang X and Yang Y. Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and-independent pathways. J Virol 2007, 81: 3170-3180.
114. Abe T, Hemmi H, Miyamoto H, Moriishi K, Tamura S, Takaku H and Akira S, et al. Involvement of the Toll-like receptor 9 signaling pathway in the induction of innate immunity by baculovirus. J Virol 2005, 79: 2847-2858.
115. Zauner L and Nadal D. Understanding TLR9 action in Epstein-Barr virus infection. Front Biosci 2012, 17: 1219-1231.
116. Nordström I and Eriksson K. HHV-6B induces IFN-lambda1 responses in cord plasmacytoid dendritic cells through TLR9. PLoS one 2012, 7: e38683.
117. Yu HR, Huang HC, Kuo HC, Sheen JM, Ou CY, Hsu TY and Yang KD. IFN-α production by human mononuclear cells infected with varicella-zoster virus through TLR9-dependent and -independent pathways. Cell Mol Immunol 2011, 8: 181-188.
118. Guggemoos S, Hangel D, Hamm S, Heit A, Bauer S and Adler H. TLR9 contributes to antiviral immunity during gammaherpesvirus infection. J Immunol 2008, 180: 438-443.
119. Samuelsson C, Hausmann J, Lauterbach H, Schmidt M, Akira S, Wagner H and Chaplin P, et al. Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection. J Clin Invest 2008, 118: 1776-1784.
120. Arpaia N, Godec J, Lau L, Sivick KE, McLaughlin LM, Jones MB and Dracheva T, et al. TLR signaling is required for Salmonella typhimurium virulence. Cell 2011, 144: 675-688.
121. Lecours MP, Segura M, Fittipaldi N, Rivest S and Gottschalk M. Immune receptors involved in Streptococcus suis recognition by dendritic cells. PLoS One 2012, 7: e44746.
122. Saiga H, Shimada Y and Takeda K. Innate immune effectors in mycobacterial infection. Clin Dev Immunol 2011, 2011: 347594.
123. Albiger B, Dahlberg S, Sandgren A, Wartha F, Beiter K, Katsuragi H and Akira S, et al. Toll-like receptor 9 acts at an early stage in host defence against pneumococcal infection. Cell Microbiol 2007, 9: 633-644.
124. Zinkernagela AS, Hruzc P, Uchiyamaa S, von Köckritz-Blickwedea M, Schuepbachd RA, Hayashic T and Carsonc DA, et al. Importance of Toll-like receptor 9 in host defense against M1T1 group A Streptococcus infections. J Innate Immun 2012, 4: 213-218.
125. Uchiyama S, Andreoni F, Schuepbach RA, Nizet V and Zinkernagel AS. DNase Sda1 allows invasive M1T1 group A Streptococcus to prevent TLR9-dependent recognition. PLoS Pathog 2012, 8: e1002736.
126. Parker D and Prince A. Staphylococcus aureus induces type I IFN signaling in dendritic cells via TLR9. J Immunol 2012, 189: 4040-4046.
127. Bafica A, Santiago HC, Goldszmid R, Ropert C, Gazzinelli RT and Sher A. Cutting edge: TLR9 and TLR2 signaling together account for MyD88-dependent control of parasitemia in Trypanosoma cruzi infection. J Immunol 2006, 177: 3515-3519.
128. Drennan MB, Stijlemans B, Van den Abbeele J, Quesniaux VJ, Barkhuizen M, Brombacher F and De Baetselier P, et al. The induction of a type I immune response following a Trypanosoma brucei infection is MyD88 dependent. J Immunol 2005, 175: 2501-2509.
129. Abou Fakher FH, Rachinel N, Klimczak M, Louis J and Doyen N. TLR9-dependent activation of dendritic cells by DNA from Leishmania major favors Th1 cell development and the resolution of lesions. J Immunol 2009, 182: 1386-1396.
130. Coban C, Igari Y, Yagi M, Reimer T, Koyama S, Aoshi T and Ohata K, et al. Immunogenicity of whole parasite vaccines against plasmodium falciparum involves malarial hemozoin and host TLR9. Cell Host Microbe 2010, 7: 50-61.
131. Parroche P, Lauw FN, Goutagny N, Latz E, Monks BG, Visintin A and Halmen KA, et al. Malaria hemozoin is immunologically inert but radically enhances innate responses by presenting malaria DNA to Toll-like receptor 9. Proc Natl Acad Sci USA 2007, 104: 1919-1924.
132. Ramirez ZG, Specht OC, Wang JP, Lee CK, Bartholomeu DC, Gazzinelli RT and Levitz SM. Toll-like receptor-9 dependent immune activation by unmethylated CpG motifs in Aspergillus fumigatus DNA. Infect Immunol 2008, 76: 2123-2129.
133. Kasperkovitz PV, Khan NS, Tam JM, Mansour MK, Davids PJ and Vyas JM. Toll-like receptor 9 modulates macrophage antifungal effector function during innate recognition of candida albicans and saccharomyces cerevisiae. Infect Immun 2011, 79: 4858-4867.
134. Bordon Y. Innate immunity: TLR13, unlucky, but just for some. Nat Rev Immunol 2012, 12: 618-619.
135. Hidmark A, von Saint Paul A and Dalpke AH. Cutting Edge: TLR13 is a receptor for bacterial RNA. J Immunol 2012, 189: 2717-2721.
136. Kleinman ME, Yamada K, Takeda A, Chandrasekaran V, Nozaki M, Baffi JZ and Albuquerque RJ, et al. Sequence-and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008, 452: 591-597.
137. Lai Y, Yi G, Chen A, Bhardwaj K, Tragesser BJ, Rodrigo AValverde and Zlotnick A, et al. Viral double-strand RNA-binding proteins can enhance innate immune signaling by Toll-like receptor 3. PLoS One 2011, 6: e25837.
138. Lai Y, Adhikarakunnathu S, Bhardwaj K, Ranjith-Kumar CT, Wen Y, Jordan JL and Wu LH, et al. LL37 and cationic peptides enhance TLR3 signaling by viral double-stranded RNAs. PLoS One 2011, 6: e26632.
139. Liu J, Xu C, Hsu LC, Luo Y, Xiang R and Chuang TH. A five-amino-acid motif in the undefined region of the TLR8 ectodomain is required for species-specific ligand recognition. Mol Immunol 2010, 47: 1083-1090.
140. Govindaraj RG, Manavalan B, Basith S and Choi S. Comparative analysis of species-specific ligand recognition in Toll-like receptor 8 signaling: a hypothesis. PLoS One 2011, 6: e25118.
141. Gorden KK, Qiu XX, Binsfeld CC, Vasilakos JP and Alkan SS. Cutting edge: activation of murine TLR8 by a combination of imidazoquinoline immune response modifiers and polyoligodeoxynucleotides. J Immunol 2006, 177: 6584-6587.
142. Demaria O, Pagni PP, Traub S, de Gassart A, Branzk N, Murphy AJ and Valenzuela DM, et al. TLR8 deficiency leads to autoimmunity in mice. J Clin Invest 2010, 120: 3651-3662.
143. Forsbach A, Nemorin JG, Montino C, Müller C, Samulowitz U, Vicari AP and Jurk M, et al. Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses. J Immunol 2008, 180: 3729-3738.
144. Ruscanu S, Pascale F, Bourge M, Hemati B, Elhmouzi-Younes J, Urien C and Bonneau M, et al. The double-stranded RNA bluetongue virus induces type I interferon in plasmacytoid dendritic cells via a MYD88-dependent TLR7/8-independent signaling pathway. J Virol 2012, 86: 5817-5828.
145. Karikó K, Buckstein M, Ni H and Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 2005, 23: 165-175.
146. Barrat FJ, Meeker T, Gregorio J, Barrat FJ, Meeker T, Gregorio J and Chan JH, et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 2005, 202: 1131-1139.
147. Baumann CL, Aspalter IM, Sharif O, Pichlmair A, Blüml S, Grebien F and Bruckner M, et al. CD14 is a coreceptor of Toll-like receptors 7 and 9. J Exp Med 2010, 207: 2689-2701.
148. Cros J, Cagnard N, Woollard K, Patey N, Zhang SY, Senechal B and Puel A, et al. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity 2010, 33: 375-386.
149. Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S and Noronha A, et al. Sequence-specific potent induction of IFN-αlpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 2005, 11: 263-270.
150. Hanagata N. Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system. Int J Nanomed 2012, 7: 2181-2195.
151. Pauls E, Shpiro N, Peggie M, Young ER, Sorcek RJ, Tan L and Choi HG, et al. Essential role for IKKb in production of type I interferons by plasmacytoid dendritic cells. J Biol Chem 2012, 287: 19216-1928.
152. Siggs OM, Berger M, Krebs P, Arnold CN, Eidenschenk C, Huber C and Pirie E, et al. A mutation of Ikbkg causes immune deficiency without impairing degradation of IkappaB alpha. Proc Natl Acad Sci USA 2010, 107: 3046-3051.
153. Skaug B, Jiang X and Chen ZJ. The role of ubiquitin in NF-kappaB regulatory pathways. Annu Rev Biochem 2009, 78: 769-796.
154. Cao W, Manicassamy S, Tang H, Kasturi SP, Pirani A, Murthy N and Pulendran B. Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI3KmTOR- p70S6K pathway. Nat Immunol 2008, 9: 1157-1164.
155. Tsujimura H, Tamura T, Kong HJ, Nishiyama A, Ishii KJ, Klinman DM and Ozato K. Toll-like receptor 9 signaling activates NF-kB through IFN regulatory factor-8/IFN consensus sequence binding protein in dendritic cells. J Immunol 2004, 172: 6820-7682.
156. Kondo T, Kawai T and Akira S. Dissecting negative regulation of Toll-like receptor signaling. Trends Immunol 2012, 33: 449-458.
157. Zeng W, Xu M, Liu S, Sun L and Chen ZL. Key role of Ubc5 and lysine-63 polyubiquitination in viral activation of IRF3. Mol Cell 2009, 36: 315-25.
158. Shi HX, Liu X, Wang Q, Tang PP, Liu XY, Shan YF and Wang C. Mitochondrial ubiquitin ligase MARCH5 promotes TLR7 signaling by attenuating TANK action. PLoS Pathog 2011, 7: e1002057.
159. Saitoh T, Satoh T, Yamamoto N, Uematsu S, Takeuchi O, Kawai T and Akira S. Antiviral protein viperin promotes Toll-like receptor 7- and Toll-like receptor 9-mediated type I interferon production in plasmacytoid dendritic cells. Immunity 2011, 34: 352-363.
160. Renner F, Saul VV, Pagenstecher A, Wittwer T and Schmitz ML. Inducible SUMO modification of TANK alleviates its repression of TLR7 signaling. EMBO Rep 2011, 12: 129-135.
161. Wang C, Chen T, Zhang J, Yang M, Li N, Xu X and Cao XT. The E3 ubiquitin ligase Nrdp1 'preferentially' promotes TLR-mediated production of type I interferon. Nat Immunol 2009, 10: 744-752.
162. Nahid MA, Satoh M and Chan EK. MicroRNA in TLR signaling and endotoxin tolerance. Cell Mol Immunol 2011, 8: 388-403.
163. Yang G, Yang L, Zhao Z, Wang JJ and Zhang XB. Signature miRNAs involved in the innate immunity of invertebrates. PLoS One 2012, 7: e39015.
164. Ma X, Becker Buscaglia LE, Barker JR and Li Y. MicroRNAs in NF-kB signaling. J Mol Cell Biol 2011, 3: 159-166.
165. Chuang TH and Ulevitch RJ. Triad3A, an E3 ubiquitin-protein ligase regulating Toll-like receptors. Nat Immunol 2004, 5: 495-502.
166. Shi M, Deng W, Bi E, Mao K, Ji Y, Lin G and Wu X, et al. TRIM30 alpha negatively regulates TLR-mediated NF-kappaB activation by targeting TAB2 and TAB3 for degradation. Nat Immunol 2008, 9: 369-377.
167. Boone DL, Turer EE, Lee EG, Ahmad RC, Wheeler MT, Tsui C and Hurley P.
168. Shembade N, Ma A and Harhaj EW. Inhibition of NF-kappaB signaling by A20 through disruption of ubiquitin enzyme complexes. Science 2010, 327: 1135-1139.
169. Saitoh T, Yamamoto M, Miyagishi M, Taira K, Nakanishi M, Fujita T and Akira S, et al. A20 is a negative regulator of IFN regulatory factor 3 signaling. J Immunol 2005, 174: 1507-1512.
170. Kayagaki N, Phung Q, Chan S, Chaudhari R, Quan C, O'Rourke KM and Eby M, et al. A deubiquitinase that regulates type I interferon production. Science 2007, 318: 1628-1632.
171. Friedman CS, O'Donnell MA, Legarda-Addison D, Ng A, Cárdenas WB, Yount JS and Moran TM, et al. The tumor suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response. EMBO Rep 2008, 9: 930-936.
172. Li S, Zheng H, Mao AP, Zhong B, Li Y, Liu Y and Gao Y, et al. Regulation of virus-triggered signaling by OTUB1- and OTUB2-mediated deubiquitination of TRAF3 and TRAF6. J Biol Chem 2010, 285: 4291-4297.
173. Kawagoe T, Takeuchi O, Takabatake Y, Kato H, Isaka Y, Tsujimura T and Akira S. TANK is a negative regulator of Toll-like receptor signaling and is critical for the prevention of autoimmune nephritis. Nat Immunol 2009, 10: 965-972.
174. Cadwell K, Liu JY, Brown SL, Miyoshi H, Loh J, Lennerz JK and Kishi C, et al. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature 2008, 456: 259-263.
175. An H, Zhao W, Hou J, Zhang Y, Xie Y, Zheng YJ and Xu HM, et al. SHP-2 phosphatase negatively regulates the TRIF adaptor proteindependent type I interferon and proinflammatory cytokine production. Immunity 2006, 25: 919-928.
176. Croker BA, Lawson BR, Rutschmann S, Berger M, Eidenschenk C, Blasius AL and Moresco EM, et al. Inflammation and autoimmunity caused by a SHP1 mutation depend on IL-1, MyD88, and a microbial trigger. Proc Natl Acad Sci USA 2008, 105: 15028-15033.
177. Bao M, Hanabuchi S, Facchinetti V, Du Q, Bover L, Plumas J and Chaperot L, et al. CD2AP/SHIP1 complex positively regulates plasmacytoid dendritic cell receptor signaling by inhibiting the E3 ubiquitin ligase Cbl. J Immunol 2012, 189: 786-792.
178. Chockalingam A, Cameron JL, Brooks JC and Leifer CA. Negative regulation of signaling by a soluble form of toll-like receptor 9. Eur J Immunol 2011, 41: 2176-2184.
179. Carty M, Goodbody R, Schröder M, Stack J, Moynagh PN and Bowie AG. The human adaptor SARM negatively regulates adaptor protein TRIF-dependent toll-like receptor signaling. Nat Immunol 2006, 7: 1074-1081.
180. Janssens S, Burns K, Tschopp J and Beyaert R. Regulation of interleukin-1- and lipopolysaccharide-induced NF-kappaB activation by alternative splicing of MyD88. Curr Biol 2002, 12: 467-471.
181. Kobayashi K, Hernandez LD, Galán JE, Janeway CA, Jr, Medzhitov R and Flavell RA. IRAK-M is a negative regulator of toll-like receptor signaling. Cell 2002, 110: 191-202.
182. Burns K, Janssens S, Brissoni B, Olivos N, Beyaert R and Tschopp J. Inhibition of interleukin 1 receptor/toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J Exp Med 2003, 197: 263-268.
183. O'Neill LA, Sheedy FJ and McCoy CE. MicroRNAs: the fine-tuners of Toll-like receptor signaling. Nat Revs Immunol 2011, 11: 163-175.
184. Ceppi M, Pereira PM, Dunand-Sauthier I, Barras E, Reith W, Santos MA and Pierre P. MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells. Proc Natl Acad Sci USA 2009, 106: 2735-2740.
185. Pifer R, Benson A, Sturge CR and Yarovinsky F. UNC93B1 is essential for TLR11 activation and IL-12- dependent host resistance to Toxoplasma gondii. J Biol Chem 2011, 286: 3307-3314.
186. Yokota SI, Okabayashi T and Fujii N. The battle between virus and host: modulation of Toll-like receptor signaling pathways by virus infection. Mediators Inflamm 2010, 2010: 184328.
187. Skalsky RL and Cullen BR. Viruses, microRNAs, and host interactions. Annu Rev Microbiol 2010, 64: 123-141.
188. Celhar T, Magalhäes R and Fairhurst AM. TLR7 and TLR9 in SLE: when sensing self goes wrong. Immunol Res 2012, 53: 58-77.
189. Yanai H, Ban T, Wang Z, Choi MK, Kawamura T, Negishi H and Nakasato M, et al. HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature 2009, 462: 99-103.
190. Krieg A and Vollmer J. Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. Immunol Rev 2007, 220: 251-269.